[go: up one dir, main page]

AU2003295928A8 - Mbcats as modifiers of the beta-catenin pathway and methods of use - Google Patents

Mbcats as modifiers of the beta-catenin pathway and methods of use

Info

Publication number
AU2003295928A8
AU2003295928A8 AU2003295928A AU2003295928A AU2003295928A8 AU 2003295928 A8 AU2003295928 A8 AU 2003295928A8 AU 2003295928 A AU2003295928 A AU 2003295928A AU 2003295928 A AU2003295928 A AU 2003295928A AU 2003295928 A8 AU2003295928 A8 AU 2003295928A8
Authority
AU
Australia
Prior art keywords
mbcats
modifiers
beta
methods
catenin pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003295928A
Other versions
AU2003295928A1 (en
Inventor
Lynn Margaret Bjerke
Steven Brian Gendreau
Kim Lickteig
Emery G Dora Iii
Michael R Costa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2003295928A8 publication Critical patent/AU2003295928A8/en
Publication of AU2003295928A1 publication Critical patent/AU2003295928A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003295928A 2002-11-25 2003-11-24 Mbcats as modifiers of the beta-catenin pathway and methods of use Abandoned AU2003295928A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42886802P 2002-11-25 2002-11-25
US60/428,868 2002-11-25
PCT/US2003/037722 WO2004047761A2 (en) 2002-11-25 2003-11-24 Mbcats as modifiers of the beta-catenin pathway and methods of use

Publications (2)

Publication Number Publication Date
AU2003295928A8 true AU2003295928A8 (en) 2004-06-18
AU2003295928A1 AU2003295928A1 (en) 2004-06-18

Family

ID=32393471

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003295928A Abandoned AU2003295928A1 (en) 2002-11-25 2003-11-24 Mbcats as modifiers of the beta-catenin pathway and methods of use

Country Status (2)

Country Link
AU (1) AU2003295928A1 (en)
WO (1) WO2004047761A2 (en)

Also Published As

Publication number Publication date
WO2004047761A3 (en) 2005-03-24
WO2004047761A2 (en) 2004-06-10
AU2003295928A1 (en) 2004-06-18

Similar Documents

Publication Publication Date Title
AU2003224638A8 (en) Pdpk1s as modifiers of the p53 pathway and methods of use
EP1651956A4 (en) Melks as modifiers of the rac pathway and methods of use
EP1535067A4 (en) PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
AU2003272390A8 (en) Ampds as modifiers of the p21 pathway and methods of use
AU2003295881A8 (en) Lamps as modifiers of the p53 pathway and methods of use
AU2003299990A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003217851A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003251799A1 (en) Mchks as modifiers of the chk1 pathway and methods of use
AU2003274911A8 (en) Mrbs as modifiers of the rb pathway and methods of use
AU2003213662A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003295928A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003303094A8 (en) Mat2as as modifiers of the p53 pathway and methods of use
AU2002361654A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003251826A8 (en) Mp21s as modifiers of the p21 pathway and methods of use
AU2003294499A8 (en) Rhebs as modifiers of the rb pathway and methods of use
EP1578945A3 (en) Cct6s as modifiers of the rb pathway and methods of use
AU2003213665A8 (en) Lgals as modifiers of the chk pathway and methods of use
AU2003213693A8 (en) Mchks as modifiers of the chk pathway and methods of use
AU2003258095A1 (en) MP21S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
EP1540333A4 (en) Maxs as modifiers of the axin pathway and methods of use
AU2003278811A8 (en) Ldlrs as modifiers of the p53 pathway and methods of use
AU2003215004A8 (en) Msrebps as modifiers of the srebp pathway and methods of use
EP1587910A4 (en) Facls as modifiers of the rb pathway and methods of use
EP1687405A4 (en) Ttbks as modifiers of the beta catenin pathway and methods of use
AU2003223208A8 (en) Mp21s as modifiers of the p21 pathway and methods of use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase